Bellerophon Therapeutics (NSDQ:BLPH) touted data today from a Phase II trial of pulsed, inhaled nitric oxide in patients with pulmonary hypertension associated with chronic obstructive pulmonary disease.
The 10-patient trial was designed to evaluate the effects of pulsed, inhaled nitric oxide on targeted vasodilation and the chronic effect on hemodynamics and exercise capacity.
Get the full story at our sister site, Drug Delivery Business News.
The post Bellerophon Therapeutics touts Ph2 COPD trial of inhaled nitric oxide appeared first on MassDevice.